Table of Content

TABLE OF CONTENT

1 EXECUTIVE SUMMARY
1.1 OVERVIEW 13
1.1.1 MARKET SYNOPSIS 13

2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY 14
2.2 RESEARCH OBJECTIVE 14
2.3 LIST OF ASSUMPTIONS 14

3 RESEARCH METHODOLOGY
3.1 OVERVIEW 16
3.2 DATA MINING 16
3.3 SECONDARY RESEARCH 17
3.4 PRIMARY RESEARCH 18
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 18
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 19
3.5 FORECASTING TECHNIQUES 19
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 20
3.6.1 BOTTOM-UP APPROACH 21
3.6.2 TOP-DOWN APPROACH 21
3.7 DATA TRIANGULATION 22
3.8 VALIDATION 22

4 MARKET DYNAMICS
4.1 OVERVIEW 23
4.2 DRIVERS 24
4.2.1 RISING CARDIOVASCULAR DISORDERS 24
4.2.2 LAUNCH OF SEVERAL HEART FAILURE DRUGS AND STRONG PIPELINE 24
4.2.3 RISING SALES OF ENTRESTO DRUG 25
4.2.4 DRIVERS IMPACT ANALYSIS 26
4.3 RESTRAINTS 26
4.3.1 SIDE-EFFECTS OF THE MEDICATION 26
4.3.2 RESTRAINTS IMPACT ANALYSIS 26
4.4 OPPORTUNITIES 27
4.4.1 EXPANDING DRUGS FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION (HF-PEF) 27

5 MARKET FACTOR ANALYSIS
5.1 PORTER’S FIVE FORCES MODEL 28
5.1.1 THREAT OF NEW ENTRANTS 28
5.1.2 BARGAINING POWER OF SUPPLIERS 29
5.1.3 THREAT OF SUBSTITUTES 29
5.1.4 BARGAINING POWER OF BUYERS 29
5.1.5 INTENSITY OF RIVALRY 29
5.2 VALUE CHAIN ANALYSIS 30
5.2.1 R&D AND DESIGNING 31
5.2.2 MANUFACTURING 31
5.2.3 DISTRIBUTION 31
5.2.4 MARKETING & SALES 31
5.2.5 POST-SALES MONITORING 31

6 GLOBAL HEART FAILURE DRUGS MARKET, BY TREATMENT TYPE
6.1 OVERVIEW 32
6.2 BETA-BLOCKERS 33
6.3 ACE INHIBITORS 34
6.4 ANGIOTENSIN-RECEPTOR NEPRILYSIN INHIBITORS (ARNI) 35
6.5 ANGIOTENSIN RECEPTOR BLOCKERS (ARBS) 36
6.6 DIURETIC 36
6.7 OTHERS 37

7 GLOBAL HEART FAILURE DRUGS MARKET, BY END USER
7.1 OVERVIEW 38
7.2 HOSPITALS 39
7.3 SPECIALTY CENTERS 39
7.4 OTHERS 40

8 GLOBAL HEART FAILURE DRUGS MARKET, BY REGION
8.1 OVERVIEW 41
8.2 AMERICAS 42
8.2.1 NORTH AMERICA 44
8.2.2 LATIN AMERICA 47
8.3 EUROPE 48
8.3.1 WESTERN EUROPE 50
8.3.2 EASTERN EUROPE 58
8.4 ASIA-PACIFIC 59
8.4.1 JAPAN 61
8.4.2 CHINA 62
8.4.3 INDIA 63
8.4.4 SOUTH KOREA 64
8.4.5 AUSTRALIA 65
8.4.6 REST OF ASIA PACIFIC 66
8.5 MIDDLE EAST & AFRICA 67
8.5.1 MIDDLE EAST 69
8.5.2 AFRICA 70

9 COMPETITIVE LANDSCAPE: GLOBAL HEART FAILURE DRUGS MARKET
9.1 OVERVIEW 71
9.2 COMPETITIVE ANALYSIS 71
9.3 COMPETITIVE BENCHMARKING 72
9.4 MAJOR GROWTH STRATEGY IN THE GLOBAL HEART FAILURE DRUGS MARKET 73
9.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 73
9.6 KEY DEVELOPMENTS AND GROWTH STRATEGIES 74
9.6.1 ACQUISITION 74
9.6.2 PRODUCT APPROVAL AND LAUNCH 74
9.6.3 COLLABORATION 75
9.7 MAJOR PLAYERS FINANCIAL MATRIX & MARKET RATIO 75
9.7.1 SALES & OPERATING INCOME 75
9.7.2 R&D EXPENDITURE 76

10 COMPANY PROFILES
10.1 AMGEN INC. 77
10.1.1 COMPANY OVERVIEW 77
10.1.2 FINANCIAL OVERVIEW 77
10.1.3 PRODUCTS/SERVICES OFFERED 78
10.1.4 KEY DEVELOPMENT 78
10.1.5 SWOT ANALYSIS 78
10.1.6 KEY STRATEGIES 78
10.2 ASTRAZENECA 79
10.2.1 COMPANY OVERVIEW 79
10.2.2 FINANCIAL OVERVIEW 79
10.2.3 PRODUCTS/SERVICES OFFERED 80
10.2.4 ASTRAZENECA: KEY DEVELOPMENTS 80
10.2.5 SWOT ANALYSIS 81
10.2.6 KEY STRATEGIES 81
10.3 NOVARTIS AG 82
10.3.1 COMPANY OVERVIEW 82
10.3.2 FINANCIAL OVERVIEW 82
10.3.3 PRODUCTS/SERVICES OFFERED 83
10.3.4 KEY DEVELOPMENTS 83
10.3.5 SWOT ANALYSIS 83
10.3.6 KEY STRATEGIES 84
10.4 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 85
10.4.1 COMPANY OVERVIEW 85
10.4.2 FINANCIAL OVERVIEW 85
10.4.3 PRODUCTS/SERVICES OFFERED 86
10.4.4 KEY DEVELOPMENTS 86
10.4.5 SWOT ANALYSIS 86
10.4.6 KEY STRATEGIES 86
10.5 BAYER AG 87
10.5.1 COMPANY OVERVIEW 87
10.5.2 FINANCIAL OVERVIEW 87
10.5.3 PRODUCTS/SERVICES OFFERED 88
10.5.4 KEY DEVELOPMENTS 88
10.5.5 SWOT ANALYSIS 88
10.5.6 KEY STRATEGIES 89
10.6 JOHNSON & JOHNSON SERVICES, INC. 90
10.6.1 COMPANY OVERVIEW 90
10.6.2 FINANCIAL OVERVIEW 90
10.6.3 PRODUCTS/SERVICES OFFERED 91
10.6.4 KEY DEVELOPMENTS 91
10.6.5 SWOT ANALYSIS 91
10.6.6 KEY STRATEGIES 92
10.7 BRISTOL-MYERS SQUIBB COMPANY 93
10.7.1 COMPANY OVERVIEW 93
10.7.2 FINANCIAL OVERVIEW 93
10.7.3 PRODUCTS/SERVICES OFFERED 94
10.7.4 KEY DEVELOPMENTS 94
10.7.5 SWOT ANALYSIS 95
10.7.6 KEY STRATEGIES 95
10.8 MERCK SHARP & DOHME CORP. 96
10.8.1 COMPANY OVERVIEW 96
10.8.2 FINANCIAL OVERVIEW 96
10.8.3 PRODUCTS/SERVICES OFFERED 97
10.8.4 KEY DEVELOPMENTS 97
10.8.5 SWOT ANALYSIS 97
10.8.6 KEY STRATEGIES 98
10.9 PFIZER, INC. 99
10.9.1 COMPANY OVERVIEW 99
10.9.2 FINANCIAL OVERVIEW 99
10.9.3 PRODUCTS/SERVICES OFFERED 100
10.9.4 KEY DEVELOPMENTS 100
10.9.5 SWOT ANALYSIS 100
10.9.6 KEY STRATEGIES 101
10.10 GILEAD SCIENCES, INC. 102
10.10.1 COMPANY OVERVIEW 102
10.10.2 FINANCIAL OVERVIEW 102
10.10.3 PRODUCTS/SERVICES OFFERED 103
10.10.4 KEY DEVELOPMENTS 103
10.10.5 SWOT ANALYSIS 103
10.10.6 KEY STRATEGIES 103

11 APPENDIX
11.1 REFERENCES 104
11.2 RELATED REPORTS 104



List of Figures


FIGURE 1 GLOBAL HEART FAILURE DRUGS MARKET STRUCTURE 15
FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES 20
FIGURE 3 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL HEART FAILURE DRUGS MARKET 23
FIGURE 4 PORTER’S FIVE FORCES ANALYSIS: GLOBAL HEART FAILURE DRUGS MARKET 28
FIGURE 5 VALUE CHAIN ANALYSIS OF THE GLOBAL HEART FAILURE DRUGS MARKET 30
FIGURE 6 GLOBAL HEART FAILURE DRUGS MARKET, BY TYPE, 2018 & 2025 (USD MILLION) 32
FIGURE 7 GLOBAL HEART FAILURE DRUGS MARKET, BY END USER, 2018 & 2025 (USD MILLION) 38
FIGURE 8 GLOBAL HEART FAILURE DRUGS MARKET, BY REGION, 2018 & 2025 (USD MILLION) 41
FIGURE 9 AMERICAS: HEART FAILURE DRUGS MARKET SHARE, BY REGION 2018 (%) 42
FIGURE 10 NORTH AMERICA: HEART FAILURE DRUGS MARKET SHARE, BY COUNTRY 2018 (%) 44
FIGURE 11 EUROPE: HEART FAILURE DRUGS MARKET SHARE, BY REGION 2018 (%) 48
FIGURE 12 WESTERN EUROPE: HEART FAILURE DRUGS MARKET SHARE, BY COUNTRY 2018 (%) 50
FIGURE 13 ASIA-PACIFIC: HEART FAILURE DRUGS MARKET SHARE, BY COUNTRY 2018 (%) 59
FIGURE 14 MIDDLE EAST & AFRICA: HEART FAILURE DRUGS MARKET SHARE, BY REGION 2018 (%) 67
FIGURE 15 BENCHMARKING OF MAJOR COMPETITORS 72
FIGURE 16 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL HEART FAILURE DRUGS MARKET 73
FIGURE 17 HEART FAILURE DRUGS MARKET, COMPETITIVE LANDSCAPE (% SHARE) 74
FIGURE 18 SALES & OPERATING INCOME 2018 75
FIGURE 19 MAJOR PLAYERS R&D EXPENDITURE 2018 76
FIGURE 20 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT 77
FIGURE 21 AMGEN INC.: SWOT ANALYSIS 78
FIGURE 22 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT 79
FIGURE 23 ASTRAZENECA: SWOT ANALYSIS 81
FIGURE 24 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 82
FIGURE 25 NOVARTIS AG: SWOT ANALYSIS 83
FIGURE 26 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: FINANCIAL OVERVIEW SNAPSHOT 85
FIGURE 27 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SWOT ANALYSIS 86
FIGURE 28 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT 87
FIGURE 29 BAYER AG: SWOT ANALYSIS 88
FIGURE 30 JOHNSON & JOHNSON SERVICES, INC.: FINANCIAL OVERVIEW SNAPSHOT 90
FIGURE 31 JOHNSON & JOHNSON SERVICES, INC.: SWOT ANALYSIS 91
FIGURE 32 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT 93
FIGURE 33 BRISTOL-MYERS SQUIBB COMPANY: SWOT ANALYSIS 95
FIGURE 34 MERCK SHARP & DOHME CORP.: FINANCIAL OVERVIEW SNAPSHOT 96
FIGURE 35 MERCK SHARP & DOHME CORP.: SWOT ANALYSIS 97
FIGURE 36 PFIZER, INC.: FINANCIAL OVERVIEW SNAPSHOT 99
FIGURE 37 PFIZER, INC.: SWOT ANALYSIS 100
FIGURE 38 PFIZER, INC.: FINANCIAL OVERVIEW SNAPSHOT 102
FIGURE 39 GILEAD SCIENCES, INC.: SWOT ANALYSIS 103


List of Tables


TABLE 1 LIST OF ASSUMPTIONS 14
TABLE 2 GLOBAL HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 33
TABLE 3 GLOBAL HEART FAILURE DRUGS MARKET FOR BETA-BLOCKERS, BY REGION, 2016–2025 (USD MILLION) 33
TABLE 4 GLOBAL HEART FAILURE DRUGS MARKET FOR ACE INHIBITORS, BY REGION, 2016–2025 (USD MILLION) 34
TABLE 5 GLOBAL HEART FAILURE DRUGS MARKET FOR ANGIOTENSIN-RECEPTOR NEPRILYSIN INHIBITORS (ARNI), BY REGION 2016–2025 (USD MILLION) 35
TABLE 6 GLOBAL HEART FAILURE DRUGS MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), BY REGION 2016–2025 (USD MILLION) 36
TABLE 7 GLOBAL HEART FAILURE DRUGS MARKET FOR DIURETIC, BY REGION, 2016–2025 (USD MILLION) 36
TABLE 8 GLOBAL HEART FAILURE DRUGS MARKET FOR OTHERS, BY REGION, 2016–2025 (USD MILLION) 37
TABLE 9 GLOBAL HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 38
TABLE 10 GLOBAL HEART FAILURE DRUGS MARKET FOR HOSPITALS, BY REGION, 2016–2025 (USD MILLION) 39
TABLE 11 GLOBAL HEART FAILURE DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2016–2025 (USD MILLION) 39
TABLE 12 GLOBAL HEART FAILURE DRUGS MARKET FOR OTHERS, BY REGION, 2016–2025 (USD MILLION) 40
TABLE 13 GLOBAL HEART FAILURE DRUGS MARKET, BY REGION, 2016–2025 (USD MILLION) 41
TABLE 14 AMERICAS: HEART FAILURE DRUGS MARKET, BY REGION, 2016–2025 (USD MILLION) 42
TABLE 15 AMERICAS: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 43
TABLE 16 AMERICAS: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 43
TABLE 17 NORTH AMERICA: HEART FAILURE DRUGS MARKET, BY COUNTRY, 2016–2025 (USD MILLION) 44
TABLE 18 NORTH AMERICA: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 44
TABLE 19 NORTH AMERICA: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 45
TABLE 20 US: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 45
TABLE 21 US: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 45
TABLE 22 CANADA: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 46
TABLE 23 CANADA: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 46
TABLE 24 LATIN AMERICA: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 47
TABLE 25 LATIN AMERICA: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 47
TABLE 26 EUROPE: HEART FAILURE DRUGS MARKET, BY REGION, 2016–2025 (USD MILLION) 48
TABLE 27 EUROPE: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 49
TABLE 28 EUROPE: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 49
TABLE 29 WESTERN EUROPE: HEART FAILURE DRUGS MARKET, BY COUNTRY, 2016–2025 (USD MILLION) 50
TABLE 30 WESTERN EUROPE: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 51
TABLE 31 WESTERN EUROPE: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 51
TABLE 32 GERMANY: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 52
TABLE 33 GERMANY: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 52
TABLE 34 UK: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 53
TABLE 35 UK: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 53
TABLE 36 FRANCE: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 54
TABLE 37 FRANCE: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 54
TABLE 38 ITALY: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 55
TABLE 39 ITALY: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 55
TABLE 40 SPAIN: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 56
TABLE 41 SPAIN: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 56
TABLE 42 REST OF WESTERN EUROPE: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 57
TABLE 43 REST OF WESTERN EUROPE: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 57
TABLE 44 EASTERN EUROPE: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 58
TABLE 45 EASTERN EUROPE: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 58
TABLE 46 ASIA-PACIFIC: HEART FAILURE DRUGS MARKET, BY COUNTRY, 2016–2025 (USD MILLION) 59
TABLE 47 ASIA-PACIFIC: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 60
TABLE 48 ASIA-PACIFIC: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 60
TABLE 49 JAPAN: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 61
TABLE 50 JAPAN: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 61
TABLE 51 CHINA: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 62
TABLE 52 CHINA: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 62
TABLE 53 INDIA: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 63
TABLE 54 INDIA: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 63
TABLE 55 SOUTH KOREA: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 64
TABLE 56 SOUTH KOREA: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 64
TABLE 57 AUSTRALIA: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 65
TABLE 58 AUSTRALIA: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 65
TABLE 59 REST OF ASIA-PACIFIC: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 66
TABLE 60 REST OF ASIA-PACIFIC: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 66
TABLE 61 MIDDLE EAST & AFRICA: HEART FAILURE DRUGS MARKET, BY REGION, 2016–2025 (USD MILLION) 67
TABLE 62 MIDDLE EAST & AFRICA: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 68
TABLE 63 MIDDLE EAST & AFRICA: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 68
TABLE 64 MIDDLE EAST: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 69
TABLE 65 MIDDLE EAST: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 69
TABLE 66 AFRICA: HEART FAILURE DRUGS MARKET, BY TYPE, 2016–2025 (USD MILLION) 70
TABLE 67 AFRICA: HEART FAILURE DRUGS MARKET, BY END USER, 2016–2025 (USD MILLION) 70
TABLE 68 TOP PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE HEART FAILURE DRUGS MARKET 73
TABLE 69 ACQUISITION: GLOBAL HEART FAILURE DRUGS MARKET 74
TABLE 70 PRODUCT APPROVAL AND LAUNCH: GLOBAL HEART FAILURE DRUGS MARKET 74
TABLE 71 COLLABORATION: GLOBAL HEART FAILURE DRUGS MARKET 75
TABLE 72 AMGEN INC.: PRODUCTS/SERVICES OFFERED 78
TABLE 73 ASTRAZENECA: PRODUCTS/SERVICES OFFERED 80
TABLE 74 KEY DEVELOPMENTS 80
TABLE 75 NOVARTIS AG: PRODUCTS/SERVICES OFFERED 83
TABLE 76 KEY DEVELOPMENTS 83
TABLE 77 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS/SERVICES OFFERED 86
TABLE 78 BAYER AG: PRODUCTS/SERVICES OFFERED 88
TABLE 79 BAYER AG: KEY DEVELOPMENTS 88
TABLE 80 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS/SERVICES OFFERED 91
TABLE 81 JOHNSON & JOHNSON SERVICES, INC: KEY DEVELOPMENTS 91
TABLE 82 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS/SERVICES OFFERED 94
TABLE 83 BRISTOL-MYERS SQUIBB COMPANY: KEY DEVELOPMENTS 94
TABLE 84 MERCK SHARP & DOHME CORP.: PRODUCTS/SERVICES OFFERED 97
TABLE 85 PFIZER, INC.: PRODUCTS/SERVICES OFFERED 100
TABLE 86 PFIZER, INC.: KEY DEVELOPMENTS 100
TABLE 87 GILEAD SCIENCES, INC.: PRODUCTS/SERVICES OFFERED 103